Patients with PD-L1 expression in tumor cells had significantly lower 5-year OS rate (50.0% vs. 67.3%, P = 0.02) and 5-year PFS rate (39.6% vs. 59.6%, P = 0.01) than did patients without PD-L1 expression in tumor cells; the 5-year OS and PFS rates were similar between patients with and without PD-L1 expression in tumor microenvironment (Fig. 1). Here, CD274 is linked to neoplasm.